Shilpa Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SHILPA, and when can generic versions of SHILPA drugs launch?
SHILPA has thirteen approved drugs.
There are five US patents protecting SHILPA drugs. There are two tentative approvals on SHILPA drugs.
There are fifty-four patent family members on SHILPA drugs in twenty-six countries and forty-eight supplementary protection certificates in sixteen countries.
Summary for Shilpa
International Patents: | 54 |
US Patents: | 5 |
Tradenames: | 11 |
Ingredients: | 11 |
NDAs: | 13 |
Patent Litigation for Shilpa: | See patent lawsuits for Shilpa |
Drugs and US Patents for Shilpa
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shilpa | CAPECITABINE | capecitabine | TABLET;ORAL | 207456-002 | Dec 12, 2016 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Shilpa Medicare | AZACITIDINE | azacitidine | POWDER;INTRAVENOUS, SUBCUTANEOUS | 207518-001 | Sep 29, 2016 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Shilpa | DOCETAXEL | docetaxel | INJECTABLE;INJECTION | 205934-002 | Dec 22, 2015 | AP | RX | Yes | Yes | 9,308,195 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
Shilpa | DOCETAXEL | docetaxel | INJECTABLE;INJECTION | 205934-001 | Dec 22, 2015 | AP | RX | Yes | Yes | 10,842,770 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
Shilpa | APREMILAST | apremilast | TABLET;ORAL | 211774-003 | Apr 7, 2023 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Shilpa | DOCETAXEL | docetaxel | INJECTABLE;INJECTION | 210327-003 | May 16, 2019 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Shilpa Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Jordan | 3685 | ⤷ Try a Trial |
Malaysia | 173324 | ⤷ Try a Trial |
Singapore | 10201503234S | ⤷ Try a Trial |
New Zealand | 603828 | ⤷ Try a Trial |
Colombia | 6640232 | ⤷ Try a Trial |
China | 102970990 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Shilpa Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1667986 | 28/2013 | Austria | ⤷ Try a Trial | PRODUCT NAME: DIMETHOXYDOCETAXEL-ACETONSOLVAT (CABAZITAXEL-ACETONSOLVAT); REGISTRATION NO/DATE: EU/1/11/676/001 20110317 |
0432677 | 7/2005 | Austria | ⤷ Try a Trial | PRODUCT NAME: PEMETREXED UND DESSEN PHARMAZEUTISCH ANNAHMBAREN SALZE; REGISTRATION NO/DATE: EU/1/04/290/001 20040920 |
0275821 | 01C0035 | France | ⤷ Try a Trial | PRODUCT NAME: ZOLEDRONIC ACID; NAT REG. NO/DATE: EU/1/01/176/001 20010320; FIRST REG.: LI IKS N 55 463 20001128 |
0122707 | SPC/GB95/031 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: GEMCITABINE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY- ACCEPTABLE SALT; REGISTERED: NL RVG17854 19950327; UK 00006/0301 19951026; UK 00006/0302 19951026 |
0258618 | SPC/GB01/042 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: ZOLEDRONIC ACID 2-(IMIDAZOL-1-YL)-1-HYDROXYETHANE-1,1-DIPHOSPHONIC ACID; REGISTERED: CH 55463 20001128; UK EU/1/01/176/001 20010320; UK EU/1/01/176/002 20010320; UK EU/1/01/176/003 20010320 |
1746976 | 300885 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: IRINOTECANSUCROSOFAATZOUT; REGISTRATION NO/DATE: EU/1/16/1130 20161018 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.